Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6712884 | 0.94 | CYP1A2 (0.34) | CYP1A2CYP19A1CYP2C9CYP2C19CHRNB2 | |
| SCHEMBL6257045 | 0.78 | HRH3 (0.32) | HRH3 | |
| SCHEMBL20320538 | 0.78 | POLB (0.38) | CYP1A2CYP19A1CYP2C9CYP2C19MEN1 | |
| SCHEMBL18483392 | 0.76 | HCAR2 (0.32) | MEN1KMT2A | |
| SCHEMBL14530597 | 0.73 | POLB (0.36) | CYP1A2CYP19A1CYP2C9CYP2C19CHRNB2 | |
| SCHEMBL14724231 | 0.73 | MEN1 (0.34) | CYP1A2CYP19A1CYP2C9CYP2C19CHRNB2 | |
| SCHEMBL20320522 | 0.72 | ALDH1A1 (0.39) | MEN1KMT2A | |
| SCHEMBL20320536 | 0.72 | HCAR2 (0.38) | MEN1KMT2A | |
| SCHEMBL22859307 | 0.70 | — | — | |
| SCHEMBL20320323 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192771-A1 | Ether compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2004-09-30 | — | — | US | claimed |
| US-20030018013-A1 | Ether compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2003-01-23 | — | — | US | claimed |
| US-6713507-B2 | CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; ALZHEIMER'S DISEASE | ESPERION THERAPEUTICS, INC. | 2004-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018013-A1 | Ether compounds and compositions for cholesterol management and related uses | GPR119, PNLIP, NR1H2 | CYP1A2 367/4885CYP19A1 79/4885CYP2C9 686/4885 |
| US-20040192771-A1 | Ether compounds and compositions for cholesterol management and related uses | GPR119, PNLIP, NR1H2 | CYP1A2 367/4885CYP19A1 79/4885CYP2C9 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.